The current data collectively supports the notion that higher expression of MUC2 and MUC5AC confers genetic and molecular features on colorectal carcinomas that incur adverse consequences in relation to treatment response and clinical outcome [9]. The gene discussed is MUC5AC; the disease is colorectal carcinoma.